• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Alliance Global Partners initiated coverage on Sorrento Therapeutics

    1/21/21 10:28:55 AM ET
    $SRNE
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SRNE alert in real time by email
    Alliance Global Partners initiated coverage of Sorrento Therapeutics with a rating of Buy and set a new price target of $35
    Get the next $SRNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRNE

    DatePrice TargetRatingAnalyst
    11/2/2022$5.00Overweight
    Cantor Fitzgerald
    8/9/2021$30.00 → $26.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SRNE
    Leadership Updates

    Live Leadership Updates

    See more
    • Scilex Holding Company, a Sorrento Company, announces that the Honorable Tommy G. Thompson has joined the Scilex Board of Directors

      PALO ALTO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, to its Board of Directors. Governor Thompson's appointment is effective immediately. Governor Thompson currently serves as the Chief Executive Officer of Thomp

      7/5/22 2:04:42 PM ET
      $SRNE
      $VCKA
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji

      SAN DIEGO, June 24, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of the Honorable Tommy G. Thompson, former Secretary of the United States Department of Health and Human Services ("HHS") and former Governor of Wisconsin, as Covid-19 special consultant to Sorrento's Chairman and CEO Henry Ji. Governor Thompson's appointment is effective immediately. Most recently, Thompson served as the President of the University of Wisconsin System from July 2020 through March 2022, one of the largest

      6/24/22 3:38:28 PM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

      SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (NASDAQ:SRNE, "Sorrento"))), a commercial and clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies and diagnostics, announced today the appointment of former Roche Laboratories executive, Tammy Reilly, to Sorrento's board of directors. Ms. Reilly brings more than 30 years of life science, big pharma and operating leadership experience within healthcare therapeutics, consumer merchandising and healthcare diagnostic companies to Sorrento.  "Sorrento continues to strengthen its already experienced board of directors," said Henry Ji, Ph.D., Chairman and Chief Executive O

      5/18/22 9:00:00 AM ET
      $SRNE
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care